Physician profile
Francis E Buckman
NPI 1912983453
$1,887.29
in general payments reported to CMS, 2019-2025
23 companies · $91.88 in 2025
The $91.88 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $316 · 2021: $170 · 2022: $230 · 2023: $365 · 2024: $308 · 2025: $91.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $304.53 | 2022-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $300.04 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.99 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $127.30 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $123.54 | 2019-2023 | Camzyos |
| Allergan, INC. | $114.60 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.93 | 2019-2020 | |
| Abbvie INC. | $104.79 | 2021-2023 | Teflaro |
| Alexion Pharmaceuticals, INC. | $99.73 | 2019-2024 | Ultomiris |
| Smith+Nephew, INC. | $51.51 | 2022 | |
| Pfizer INC. | $40.10 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $39.63 | 2020-2021 | |
| Scpharmaceuticals INC. | $33.27 | 2024 | |
| Boston Scientific Corporation | $32.76 | 2023 | Watchman Access System |
| Janssen Scientific Affairs, LLC | $30.36 | 2023 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $30.29 | 2021 | |
| Vifor Pharma, INC. | $29.26 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $27.20 | 2019-2020 | |
| Recor Medical INC | $25.79 | 2024 | Paradise Renal Denervation System |
| Urgo Medical North America, LLC | $16.06 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Gilead Sciences, INC. | $16.04 | 2025 | Veklury |
| Otsuka America Pharmaceutical, INC. | $14.42 | 2019 | |
| Biomerieux INC | $8.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Buckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.